Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 15/20 | 0.80 |
| ▸ | PGR | P06401 | 1/20 | 0.80 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8517259 | 1.00 | AR (0.80) | ARPGRHDAC1 | |
| SCHEMBL1714908 | 0.99 | AR (0.82) | ARPGRHDAC1 | |
| SCHEMBL29453440 | 0.99 | AR (0.82) | ARPGRHDAC1 | |
| SCHEMBL2693558 | 0.96 | AR (0.81) | ARPGRHDAC1 | |
| SCHEMBL4020463 | 0.92 | AR (0.77) | ARPGRHDAC1 | |
| SCHEMBL30291848 | 0.92 | AR (0.77) | ARPGRHDAC1 | |
| SCHEMBL20003388 | 0.90 | AR (0.78) | ARPGRHDAC1 | |
| SCHEMBL3873391 | 0.90 | AR (0.75) | ARPGRHDAC1 | |
| SCHEMBL3871464 | 0.90 | AR (0.75) | ARPGRHDAC1 | |
| SCHEMBL20003480 | 0.90 | AR (0.78) | ARPGRHDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7601748-B2 | Anti-androgenic N-[ omega -[3-[4-cyano-3-(trifluoromethyl)-phenyl]-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl]alkyl]-substituted pyrrolidines; treatment of prostate cancer, benign prostate hyperplasia, androgenetic alopecia, hirsutism or acne | BAYER SCHERING PHARMA AG (DE) | 2009-10-13 | — | — | US | disclosed |
| EP-1622894-B1 | ANTITUMORAL ANTIANDROGENIC PYRROLIDINES | BAYER SCHERING PHARMA AG (DE) | 2009-01-14 | — | — | EP | disclosed |
| US-20070021481-A1 | Anti-androgenic pyrrolidines with tumor-inhibiting action | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-01-25 | — | — | US | disclosed |
| US-7138421-B2 | Anti-androgenic pyrrolidines with tumor-inhibiting action | SCHRING AKTIENGESELLSCHAFT (DE) | 2006-11-21 | — | — | US | disclosed |
| EP-1622894-A1 | ANTITUMORAL ANTIADROGENIC PYRROLIDINES | Schering Aktiengesellschaft (DE) | 2006-02-08 | — | — | EP | disclosed |
| US-20050159468-A1 | Anti-androgenic pyrrolidines with tumor-inhibiting action | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2005-07-21 | — | — | US | disclosed |
| WO-2004099188-A1 | ANTITUMORAL ANTIADROGENIC PYRROLIDINES | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021481-A1 | Anti-androgenic pyrrolidines with tumor-inhibiting action | NR5A1, AR, CYP17A1 | AR 2/4885PGR 40/4885HDAC1 927/4885 |
| US-20050159468-A1 | Anti-androgenic pyrrolidines with tumor-inhibiting action | NR5A1, AR, CYP17A1 | AR 2/4885PGR 40/4885HDAC1 927/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.